NIKKEI 225
38,487.90 +433.80 (+1.14%) HANG SENG
18,079.61 -150.59 (-0.83%) CRUDE OIL
76.78 -0.21 (-0.27%) GOLD FUTURES
2,345.20 -0.60 (-0.03%) DOW
38,686.32 +574.82 (+1.51%) Bitcoin GBP
53,258.71 +107.62 (+0.20%)
DTIL Jun 2024 2.500 call
- Business Wire
Precision BioSciences to Participate in Upcoming June Investor Conferences
DURHAM, N.C., May 30, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that members of management will participate in the following upcoming investor conferences in June:
- Zacks
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., May 17, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on May 13, 2024, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement
